Gendron, Louis

Directeur de département, Faculté de médecine et des sciences de la santé
FMSS Département de pharmacologie-physiologie

Coordonnées

Courriel


819-821-8000, poste 72760


Site Web

Diplômes

(2006) Post-doctorate (Postdoc). University of Washington.

(2005) Post-doctorate (Postdoc). McGill University.

(2003) Doctorate (Doctorate). Université de Sherbrooke.

(2000) Master's Thesis (Master - Masters). Université de Sherbrooke.

(1997) Bachelor's (Bachelor). Université de Sherbrooke.

Expérience académique

(2016) Professeur/Full Professor. Université de Sherbrooke.

Présentation

Sujets de recherche

Pain, Cell Signaling, Receptors and Carriers, Arthritis / Osteo-Arthritis, Anxiety.

Disciplines de recherche

Neurosciences, Cell Biology, Pharmacology.

Mots-clés

opioids, delta opioid receptor, pain, cell signaling, GPCR, tolerance, dorsal root ganglion, desensitization, immunolabeling, electron microscopy.

Intérêts de recherche

Receptor pharmacology, in vivo pharmacology, pain, opioids, side effects, receptor signaling

Centre de recherche

Centre de recherche du CHUS

Langues parlées et écrites

Anglais, Français

Prix et distinctions

  • (2019) Nominé/Nominee - Prix Pharmacologie. Université de Sherbrooke. (Prize / Award).
  • (2017) Mention d'honneur du Doyen, performance professorale exceptionnelle. Université de Sherbrooke. (Honor).
  • (2016) Mention d'honneur du Doyen, performance professorale exceptionnelle. Université de Sherbrooke. (Honor).
  • (2016) Nominé/Nominee - Prix Pharmacologie. Université de Sherbrooke. (Prize / Award).
  • (2015) Mention d'honneur du Doyen, performance professorale exceptionnelle. Université de Sherbrooke. (Honor).
  • (2015) Nominé/Nominee - Prix Pierre-et-Danielle-Bourgaux. Université de Sherbrooke. (Prize / Award).
  • (2015) Prix du Doyen. Université de Sherbrooke. (Prize / Award).
  • (2014) Mention d'honneur du Doyen, performance professorale exceptionnelle. Université de Sherbrooke. (Honor).
  • INRC Young Investigator Award. International Narcotics Research Conference. (Prize / Award).
  • Nominé/Nominee - Prix Diego-Bellabarba (mentorat). Université de Sherbrooke. (Prize / Award).

Financement

Grant. (Awarded). Principal Investigator. Role, function, and regulation of the delta opioid receptor and its implications for the treatment of pain (ranked 3rd). Canadian Institutes of Health Research (CIHR). Project Grant Competition. 967725 $ (2019-2024).

Grant. (Awarded). Principal Investigator. Neurobiology and molecular mechanisms of the opioid system. Natural Sciences and Engineering Research Council of Canada (NSERC). Discovery Grant. 145000 $ (2018-2023).

Grant. (Awarded). Co-applicant. Novel Supramolecular Drugs for a “Supramolecular” Disease. Fonds de recherche du Québec - Nature et technologies (FRQNT). Fonds de la Recherche Scientifique - FNRS. Programme bilatéral de recherche collaborative Québec-Fédération Wallonie-Bruxelles. 300000 $ (2019-2022).

Grant. (Awarded). Co-applicant. Chronic Pain Network (Strategy for Patient–Oriented Research (SPOR) Networks in Chronic Disease). Canadian Institutes of Health Research (CIHR) and partnerships. Strategy for Patient–Oriented Research (SPOR) Networks in Chronic Disease. 25000000 $ (2016-2021).

Grant. (Awarded). Co-investigator. Médicaments supramoléculaires pour maladies supramoléculaires. Institut de pharmacologie de Sherbrooke (IPS). concours IPS-Innovation. 30000 $ (2018-2020).

Grant. (Awarded). Principal Applicant. Planning and Dissemination Grant - 20th Joint meeting of the Great Lakes GPCR Retreat and the Club des récepteurs à sept domaines transmembranaires du Québec (ranked 1st). Canadian Institutes of Health Research (CIHR). Planning and Dissemination Grant. 20000 $ (2019-2020).

Grant. (Awarded). Co-applicant. Planning and Dissemination Grant - Dissiper la fumée : Cannabis et Santé Colloque scientifique conjoint du Réseau québécois de recherche sur les médicaments, du Réseau santé respiratoire et du Réseau québécois de recherche sur la douleur. Canadian Institutes of Health Research (CIHR). Planning and Dissemination Grant. 20000 $ (2019-2020).

Grant. (Awarded). Co-applicant. The potential of Cannabidiol as a therapeutic agent for concussion. Canadian Institutes of Health Research (CIHR). Catalyst Grant - Cannabis Research in Urgent Priority Areas. 125000 $ (2019-2020).

Grant. (Awarded). Principal Investigator. Design, synthesis and characterization of novel enkephalin analogs for the delta opioid receptor. (2014-2019).

Fellowship. (Completed). Principal Applicant. Rôles, régulation et mécanismes d'action des récepteurs opioïdergiques dans le contrôle de la douleur (Rang: 2/13). (2015-2019).

Grant. (Completed). Principal Investigator. Delta opioid receptor as a target for migraine-induced allodynia. RQRD-FRQS. Pilot-project grants. 25000 $ (2017-2019).

Grant. (Completed). Principal Investigator. Rôle, régulation, mécanismes d'action du récepteur opioïde delta dans le contrôle de la douleur. (2012-2018).

Publications

Articles de revue

  • Claff, T., Yu, J., Blais, V., Patel, N., Martin, C., Wu, L., Han, G.W., Holleran, B.J., Van der Poorten, O., White, K.L., Hanson, M.A., Sarret, P., Gendron, L., Cherezov, V., Katritch, V., Ballet, S., Liu, Z.-J., Müller, C.E.*, Stevens, R.C.*. (2019). Elucidating the active delta-opioid receptor crystal structure with peptide and small molecule agonists. Science Advances, nd, nd. (In Press).
  • Desbiens L , Lapointe C , Gendron L , Gharagozloo M , Vincent L , Pejler G , Gris D , D'Orleans-Juste P. (2019). Experimental autoimmune encephalomyelitis potentiates mouse mast cell protease 4-dependent pressor responses to centrally or systemically administered big endothelin-1. The Journal of pharmacology and experimental therapeutics, 370(3), 437-446. (Published).
  • Beaudeau JL , Blais V , Holleran BJ , Bergeron A , Piñeyro G , Guérin B , Gendron L , Dory YL. (2019). N-Guanidyl and C-Tetrazole Leu-Enkephalin Derivatives: Efficient Mu and Delta Opioid Receptor Agonists with Improved Pharmacological Properties. ACS chemical neuroscience, 10(3), 1615-1626. (Published).
  • Gharagozloo M , Mahmoud S , Simard C , Yamamoto K , Bobbala D , Ilangumaran S , Smith MD , Lamontagne A , Jarjoura S , Denault JB , Blais V , Gendron L , Vilariño-Güell C , Sadovnick AD , Ting JP , Calabresi PA , Amrani A , Gris D. (2019). NLRX1 inhibits the early stages of CNS inflammation and prevents the onset of spontaneous autoimmunity. PLoS biology, 17(9), e3000451. (Published).
  • Eiselt E*, Gonzalez S*, Martin C, Chartier M, Betti C, Longpré JM, Cavelier F, Tourwè D, Gendron L, Ballet S, Sarret P. (2019). Neurotensin Analogues Containing Cyclic Surrogates of Tyrosine at Position 11 Improve NTS2 Selectivity Leading to Analgesia without Hypotension and Hypothermia. ACS chemical neuroscience, nd, nd. (Accepted).
  • *Eiselt E, Côté J, Longpré JM, *Blais V, Sarret P, Gendron L. (2019). The combination of opioid and neurotensin receptor agonists improves their analgesic/adverse effect ratio. Eur. J. Pharmacol., 848:, 80-87. (Published).
  • *Abdallah K , *Nadeau F , *Bergeron F , *Blouin S , *Blais V , *Bradbury KM , Lavoie CL , Parent JL , Gendron L. (2018). Adeno-associated virus 2/9 delivery of Cre recombinase in mouse primary afferents. Scientific reports, 8(1), 7321. (Published).
  • Henry MS , Bisht K , Vernoux N , Gendron L , Torres-Berrio A , Drolet G , Tremblay MÈ. (2018). Delta Opioid Receptor Signaling Promotes Resilience to Stress Under the Repeated Social Defeat Paradigm in Mice. Frontiers in molecular neuroscience, 11, 100. (Published).
  • *Bella Ndong, D., *Blais, V., *Proteau-Gagné, A., *Holleran, B.J., *Cantin-Savoie, I., *Nadon, J.-F., *Beauchemin, S., Leduc, R., +Guérin, B., +Gendron, L., +Dory, Y.L., +Corresponding authors. (2018). Exploration of the fifth position of Leu-enkephalin and its role in binding and activating the opioid receptors. Peptide Science, 111, e24070. (Published).
  • Charfi I , *Abdallah K , Gendron L , Pineyro G. (2017). Delta opioid receptors recycle to the membrane after sorting to the degradation path. Cellular and molecular life sciences : CMLS, tbd, tbd. (Published).
  • Henry MS , Gendron L , Tremblay ME , Drolet G. (2017). Enkephalins: Endogenous Analgesics with an Emerging Role in Stress Resilience. Neural plasticity, 2017, 1546125. (Published).
  • *St-Louis É , Degrandmaison J , *Grastilleur S , Génier S , *Blais V , Lavoie C , Parent JL , Gendron L. (2017). Involvement of the coatomer protein complex I in the intracellular traffic of the delta opioid receptor. Molecular and Cellular Neuroscience, 76, 53-63. (Published).
  • *Pirisedigh A , *Blais V , Ait-Mohand S , *Abdallah K , *Holleran BJ , Leduc R , +Dory YL , +Gendron L , +Guérin B; +, corresponding authors. (2017). Synthesis and Evaluation of a (64)Cu-Conjugate, a Selective δ-Opioid Receptor Positron Emission Tomography Imaging Agent. Organic letters, 19(8), 2018-2021. (Published).
  • *Nadon JF, *Rochon K , *Grastilleur S , *Langlois G , *Dao TT , *Blais V , +Guérin B , +Gendron L , +Dory YL; +, corresponding authors. (2017). Synthesis of Gly-ψ[(Z)CF=CH]-Phe, a Fluoroalkene Dipeptide Isostere, and Its Incorporation into a Leu-enkephalin Peptidomimetic. ACS chemical neuroscience, 8(1), 40-49. (Published).
  • Van der Poorten O , Van Den Hauwe R , Eiselt E , Betti C , Guillemyn K , Chung NN , Hallé F , Bihel F , Schiller PW , Tourwé D , Sarret P , Gendron L , Ballet S. (2017). χ-Space Screening of Dermorphin-Based Tetrapeptides through Use of Constrained Arylazepinone and Quinolinone Scaffolds. ACS medicinal chemistry letters, 8(11), 1177-1182. (Published).
  • Shi M , Paquette B , Thippayamontri T , Gendron L , Guérin B , Sanche L. (2016). Increased radiosensitivity of colorectal tumors with intra-tumoral injection of low dose of gold nanoparticles. International journal of nanomedicine, 11, 5323-5333. (Published).
  • Gendron, L., Cahill, C.M., von Zastrow, M., Schiller, P.W. and Pineyro, G. (2016). Molecular pharmacology of δ-opioid receptors. Pharmacological Reviews, 68(3), 631-700. (Published).
  • *Maltais, J.-S. Simard, E., Froehlich, U., Denault, J.-B., Gendron, L. and Grandbois, M. (2016). iRAGE as a novel carboxymethylated peptide that prevents advanced glycation end product-induced apoptosis and endoplasmic reticulum stress in vascular smooth muscle cells. Pharmacological Research, 104, 176-185. (Published).
  • *Beaudry, H., +Gendron, L. and +Moron-Concepción, J.; +, corresponding authors. (2015). Implication of DOP2 but not DOP1 in development of morphine analgesic tolerance in a rat model of chronic inflammatory pain. Eur J Neurosci, 41(7), 899-905. (Published).
  • Gendron, L., Mittal, N., *Beaudry, H. and Walwyn, W. (2015). Recent advances on the delta opioid receptor: From trafficking to function. British Journal of Pharmacology, 172(2), 403-419. (Published).
  • *H Beaudry, *A-A Mercier-Blais, *C Delaygue, C Lavoie, J-L Parent, W Neugebauer and L Gendron. (2015). Regulation of [mu]- and [delta]-Opioid Receptor Functions: Involvement of Cyclin-Dependent Kinase 5. British Journal of Pharmacology, 172(10), 2573-2587. (Published).
  • Thomas JB, Giddings AM, Wiethe RW, Olepu S, Warner KR, Sarret P, Gendron L, Longpre JM, Zhang Y, Runyon SP, Gilmour BP. (2014). Identification of 1-({[1-(4-Fluorophenyl)-5-(2-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl}amino)cyclohexane Carboxylic Acid as a Selective Nonpeptide Neurotensin Receptor Type 2 Compound. Journal of Medicinal Chemistry, 57(12), 5318-5332. (Published).
  • Thomas JB, Giddings AM, Wiethe RW, Olepu S, Warner KR, Sarret P, Gendron L, Longpre JM, Zhang Y, Runyon SP, Gilmour BP. (2014). Identification of N-[(5-{[(4-methylphenyl)sulfonyl]amino}-3-(trifluoroacetyl)-1H-indol-1-yl)acetyl]-l-leucine (NTRC-824), a neurotensin-like nonpeptide compound selective for the neurotensin receptor type 2. J Med Chem, 57(17), 7472-7. (Published).
  • *Desroches, J., Bouchard, J.-F., +Gendron, L. and +Beaulieu, P.; +, corresponding authors. (2014). Involvement of cannabinoid receptors in peripheral and spinal morphine analgesia. Neuroscience, 261, 23-42. (Published).
  • *Bourassa, P., Grandbois, M. and Gendron, L. (2014). Label-Free Monitoring of Mu Opioid Receptor-Mediated Signaling. Molecular Pharmacology, 86(2), 138-149. (Published).
  • Cabañero D , Baker A , Zhou S , Hargett GL , Irie T , Xia Y , *Beaudry H , Gendron L , Melyan Z , Carlton SM , Morón JA. (2013). Pain after Discontinuation of Morphine Treatment Is Associated with Synaptic Increase of GluA4-Containing AMPAR in the Dorsal Horn of the Spinal Cord. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 38(8), 1472-1484. (Published).
  • *Rochon K , *Proteau-Gagné A , *Bourassa P , *Nadon JF , Côté J , *Bournival V , Gobeil F , Guérin B , Dory YL , Gendron L. (2013). Preparation and Evaluation at the Delta Opioid Receptor of a Series of Linear Leu-Enkephalin Analogues Obtained by Systematic Replacement of the Amides. ACS chemical neuroscience, 4(8), 1204-1216. (Published).
  • *Normandin, A., Luccarini, P., Molat, J.-L., +Gendron, L. and +Dallel, R.; +, corresponding authors. (2013). Spinal μ and δ opioids inhibit both thermal and mechanical pain in rats. The Journal of neuroscience : the official journal of the Society for Neuroscience, 33(28), 11703-11714. (Published).
  • *Proteau-Gagné, A., *Rochon, K., *Roy, M., *Albert, P.-J., +Guérin, B., +Gendron, L. and +Dory, Y.L.; +, corresponding authors. (2013). Systematic replacement of amides by 1,4-disubstituted[1,2,3]triazoles in Leu-enkephalin and the impact on the delta opioid receptor activity. Bioorganic & medicinal chemistry letters, 23(19), 5267-5269. (Published).
  • *Parent AJ , Beaudet N , *Beaudry H , *Bergeron J , Bérubé P , Drolet G , Sarret P , Gendron L. (2012). Increased anxiety-like behaviors in rats experiencing chronic inflammatory pain. Behavioural brain research, 229(1), 160-167. (Published).
  • *Maltais JS , Denault JB , Gendron L , Grandbois M. (2012). Label-free monitoring of apoptosis by surface plasmon resonance detection of morphological changes. Apoptosis : an international journal on programmed cell death, 17(8), 916-925. (Published).
  • *Beaudry H , *Dubois D , Gendron L. (2011). Activation of spinal mu- and delta-opioid receptors potently inhibits substance P release induced by peripheral noxious stimuli. The Journal of neuroscience : the official journal of the Society for Neuroscience, 31(37), 13068-13077. (Published).
  • *Bournival V , Desjardins R , Campbell S , Roberge C , Doueik A , Gendron L , Payet MD , Gallo-Payet N , Day R , Praud JP. (2011). Presence of task-1 channel in the laryngeal mucosa in the newborn lamb. Experimental lung research, 37(4), 205-211. (Published).
  • *Otis V , Sarret P , Gendron L. (2011). Spinal activation of delta opioid receptors alleviates cancer-related bone pain. Neuroscience, 183, 221-229. (Published).
  • Roussy G , *Beaudry H , Lafrance M , Belleville K , Beaudet N , Wada K , Gendron L , Sarret P. (2010). Altered morphine-induced analgesia in neurotensin type 1 receptor null mice. Neuroscience, 170(4), 1286-1294. (Published).
  • Doré-Savard L , *Otis V , Belleville K , Lemire M , Archambault M , Tremblay L , Beaudoin JF , Beaudet N , Lecomte R , Lepage M , Gendron L , Sarret P. (2010). Behavioral, medical imaging and histopathological features of a new rat model of bone cancer pain. PloS one, 5(10), e13774. (Published).
  • *Dubois D , Gendron L. (2010). Delta opioid receptor-mediated analgesia is not altered in preprotachykinin A knockout mice. The European journal of neuroscience, 32(11), 1921-1929. (Published).
  • *Proteau-Gagné A , *Bournival V , *Rochon K , Dory YL , Gendron L. (2010). Exploring the Backbone of Enkephalins To Adjust Their Pharmacological Profile for the ?-Opioid Receptor. ACS chemical neuroscience, 1(11), 757-769. (Published).

Chapitres de livre

  • Louis Gendron, Karim Nagi, Manel Zeghal, Patrick M. Giguère and Graciela Pineyro. (2019). Molecular aspects of delta opioid receptors. Gerald Litwack Vitamins and Hormones; OPIOID HORMONES (VH 111). United Kingdom : Elsevier. (Accepted).
  • Génier S , Degrandmaison J , Lavoie CL , Gendron L , Parent JL. (2019). Monitoring the Aggregation of GPCRs by Fluorescence Microscopy. Tiberi, M. Methods Mol Biol (1947, 289-302). United States : Humana Press. (Published).
  • Abdallah K , Gendron L. (2018). The Delta Opioid Receptor in Pain Control. Jutkiewicz E. Handbook of experimental pharmacology (247, 147-177). Switzerland : Springer. (Published).
  • *Bourassa, P., Söllradl, T., *Maltais, J.-S., Charette, P.G., Gendron, L., Grandbois, M. (2015). Surface Plasmon Resonance to Study Cell Signaling and GPCR Functional Selectivity in Live Cells. Fang, Ye Label-Free Biosensor Methods in Drug Discovery (53, 183-195). United States : Springer New York. (Published).

Articles de conférence

  • *Bergeron, F. *Berthiaume, S. *Quirion, B. *St-Louis, É. *Blais, V. Parent, J.-L. Lavoie, C. Gendron, L. (2018). Cdk5-mediated phosphorylation of the delta opioid receptor: a key process for the regulation of cell surface receptors. Society for Neuroscience. (Published).
  • Eiselt, E. Betti, C. Martin, C. Longpré, J.-M. Spetea, M. Ballet, S. Gendron, L. Sarret, P. (2018). Development of opioid/neurotensin bifunctional hybrid peptides for the treatment of pain. World meeting of the International Association for the Study of Pain. (Published).
  • Claff, T. *Blais, V. *Holleran, B. Patel, N. Wu, L. Yu, J. Ballet, S. Gendron, L. Katritch, V. Liu, Z.-J. Müller, C. E. Sarret, P. Stevens, R. C. (trainees and staff, then professors are listed in alphabetical order). (2018). Facilitating lipidic cubic phase crystallization experiments with newopioid receptor agonists. Annual Meeting of the German Pharmaceutical Society – DPhG. (Published).
  • *Grastilleur, S. Degrandmaison, J. *Simard, J. Parent, J.-L. Lavoie, C. Gendron, L. (2018). La régulation constitutive du récepteur aux opioïdes de type Delta (DOP) par les petites protéines G Rab5 et Rab4. Club de recherche clinique du Québec (CRCQ). (Published).
  • Van Den Hauwe, R. Van der Poorten, O. Ballet, S. *Eiselt, E. Sarret, P. Gendron, L. Tourwé, D. (2018). Synthesis of novel arylazepinone dipeptide mimetics and 1,5-benzothiazepinones as local constraints in peptidomimetic design. 35th European Peptide Symposium. (Published).
  • *Abdallah, K., Degrandmaison, J., *Blais, V., *Bradbury, K., *Bergeron, F., *Fontes, K., Lavoie, C.L., Cahill, C.M., Boulter, J., Parent, J.L. and Gendron, L. (2017). International Narcotics Research Conference. (Published).
  • *Abdallah, K., Degrandmaison, J., *Blais, V., *Bradbury, K., *Bergeron, F., *Fontes, K., Lavoie, C.L., Cahill, C.M., Boulter, J., Parent, J.L. and Gendron, L. (2017). A conditional knockin mice to study the delta opioid receptor in pain pathways. Society for Neuroscience. (Published).
  • *Eiselt, E., *Blais, V., Longpré, J.-M., Sarret, P. and Gendron, L. (2017). Combining neurotensin and opioid receptor agonists to relieve pain. Society for Neuroscience. (Published).
  • *Grastilleur, S., *Simard, J., *Blais, V., Parent, J.-L., Lavoie, C.L. and Gendron, L. (2017). DOPr displays constitutive internalization and sorting to the rapid recycling pathway. Society for Neuroscience. (Published).
  • Henry, M.S., Bisht, K., Vernoux, N., Gendron, L., Drolet, G. and Tremblay, M.-E. (2017). Delta opioid signaling promotes resilience to chronic stress in mice under the repeated social defeat paradigm. 11th Annual Canadian Neuroscience Meeting. (Published).
  • *Bella Ndong, D., Gendron, L. and Dory, Y. (2017). Développement de macrocycles ayant pour cible le récepteur opioïdergique delta (prix pour meilleur présentation). 1ere Journée scientifique Cancer-Inflammation-Douleur. (Published).
  • *Grastilleur, S., Lavoie, C. and Gendron, L. (2017). L'internalisation constitutive du récepteur opioïdergique delta. 1ere Journée scientifique Cancer-Inflammation-Douleur. (Published).
  • *Beaudeau, J.-L., *Blais, V., *Holleran, B., Guérin, B., Gendron, L. and Dory, Y. (2017). New strategies for the development of selective and optimized delta opioid receptor agonists inspired from Leu-enkephalin. American Peptide Symposium. (Published).
  • Chalaye, P., Beaudet, N., Gagnon-Mailhot, M., Damien, J., Tousignant-Laflamme, Y., Léonard, G., Gendron, L. and Marchand, S. (2017). Strategic Approaches to Personalized Diagnosis and Treatment in Chronic Pain: Standardization of Methods Evaluating Conditioned Pain Mechanisms (CPM). Chronic Pain Network Annual Meeting. (Published).
  • *Beaudeau, J.-L., Gendron, L. and Dory, Y. (2017). Synthesis and evaluation at the delta opioid receptor of analogues of Leu-enkephalin peptidomimetics with improved pharmacokinetics (prix pour meilleure présentation). 1ere Journée scientifique Cancer-Inflammation-Douleur. (Published).
  • *Eiselt, E., Gendron, L. and Sarret, P. (2017). Use of non-invasive Trojan horse strategy to improve the delivery of opioid pain relief medications to the brain. 1ere Journée scientifique Cancer-Inflammation-Douleur. (Published).
  • *Grastilleur, S., *Simard, J., Parent, J.-L., Lavoie, C. and Gendron, L. (2016). Constitutive internalization of delta opioid receptors. Society for Neuroscience. (Published).
  • *Abdallah, K., *Blais, V., *Bradbury, K., *Fontes, K., Parent, J.-L., Cahill, C.M., Boulter, J. and Gendron, L. (2016). Knockin of delta opioid receptors in primary afferents alleviates heat-induced pain. Society for Neuroscience. (Published).
  • *A. Pirisedigh, Y. L. Dory, L. Gendron and B. Guérin. (2016). Preparation and evaluation of a series of 19F-enkephalin analogues: the first step in the design of potent and selective 18F-labeled PET tracers for delta opioid receptor imaging. 252nd ACS National Meeting. (Published).
  • *Eiselt, E., *Otis, V., Belleville, K., Larocque, A., Régina, A., Longpré, J.-M., Demeule, M., Sarret, P. and Gendron, L. (2016). Use of a non-invasive Trojan horse strategy to improve the delivery of opioid pain relief medications to the brain. Society for Neuroscience meeting. (Published).
  • Iness Charfi, *Khaled Abdallah, Louis Gendron, Graciela Pineyro. (2015). Delta opioid receptor recycles from late endosomal compartments. GPCR Retreat. (Published).
  • Iness Charfi, *Khaled Abdallah, Louis Gendron, Graciela Pineyro. (2015). Delta opioid receptor recycles from late endosomal compartments. Society for Neuroscience 2015. (Published).
  • *Azadeh Pirisedigh, Yves Dory, Louis Gendron, Brigitte Guérin. (2015). Design, Synthesis and Evaluation of Selective 19F-Enkephalin Analogs; A First Step in the Development of PET Tracers for DOP Imaging. Québec and Ontario Mini-Symposium in Synthetic and Bioorganic Chemistry. (Published).
  • *Sébastien Grastilleur, Jean-Luc Parent, Christine Lavoie, Louis Gendron. (2015). Identification and characterization of interacting partners involved in the trafficking of the delta opioid receptor. GPCR Retreat. (Published).
  • L. GENDRON, E. ST-LOUIS, J.-L. PARENT. (2015). Implication of COPB1 in intracellular retention of the delta opioid receptor. Society for Neuroscience 2015. (Published).
  • *Etienne St-Louis, Jean-Luc Parent, Louis Gendron. (2015). Implication of COPB1 in intracellular retention of the delta opioid receptor. International Narcotics Research Conference. (Published).

Autres contributions

Cours enseignés

  • Writing and Publishing a Scientific Paper. EFD954. (2017-01-11). Niveau : Post Graduate.
  • Systems Physiology. (2013-01-08). Niveau : Graduate.
  • Peptide Pharmacology. PHAR703B. (2011-01-04 à 2011-12-17). Niveau : Graduate.
  • Molecular and cellular endocrinology. PHS 712. (2010-01-06 à 2014-12-20). Niveau : Graduate.
  • Principles of Pharmacology. (2010-01-05 à 2013-12-14). Niveau : Graduate.
  • Scientific interaction. PHR 712. (2009-01-06 à 2009-12-19). Niveau : Graduate.
  • Abus et dépendance. PHR 510. (2008-01-08). Niveau : Undergraduate.
  • Pharmacology of the nervous system. PHR500. (2008-01-08). Niveau : Undergraduate.
  • Chemical mediators of neurotransmission. PHR 703. (2008-01-07 à 2012-12-22). Niveau : Graduate.
  • Neurophysiology of pain. GDL 720. (2008-01-07). Niveau : Graduate.

Gestion d'évènements

  • Co-chair and Treasurer. (2019). 20th Joint meeting of the Great Lakes GPCR Retreat and the Club des récepteurs à sept domaines transmembranaires du Québec. (Conference).

Présentations

  • (2019). Le cannabis thérapeutique: Entre mythes et réalité. Association de la fibromyalgie de l'Estrie (May 4th). Sherbrooke, Canada.
  • (2019). Le cannabis thérapeutique: Entre mythes et réalité. Congrès de la Fédération des kinésiologues du Québec (May 3rd). Orford, Canada.
  • (2018). Identification of Rab10 as a regulator of the delta-opioid receptor trafficking using an epitope tagged knockin mouse. 19th Joint meeting of the Great Lakes GPCR Retreat and the Club des récepteurs à sept domaines transmembranaires du Québec (Oct 26th). Detroit, United States.
  • (2018). Le cannabis : drogue ou médicament. Le cannabis et moi (Regroupement des étudiants chercheurs de l'Université de Sherbrooke). Sherbrooke, Canada.
  • (2018). Le cannabis : drogue ou médicament. PAINtalks 2018 (Oct 5th). Quebec, Canada.
  • (2017). Investigating delta opioid receptors in a new conditional knockin mouse. International Narcotics Research Conference. Chicago, United States.
  • (2017). Targeting the Delta Opioid Receptor to Alleviate Pain. Hotchkiss Brain Institute, University of Calgary. Calgary, Canada.
  • (2017). Traiter la douleur, un défi de taille. 1ere Journée scientifique en Cancer-Inflammation-Douleur. Orford, Canada.
  • (2016). Molecular mechanisms controlling the delta opioid receptor trafficking. Department of Physiology, McGill University. Montreal, Canada.
  • (2016). Rôle de la boucle i2 dans la régulation du récepteur opioïde delta. Université d’Auvergne. Clermont-Ferrand, France.
  • (2016). Rôle de la voie de sécrétion régulée dans le contrôle des fonctions analgésiques du récepteur opioïde delta. Congrès de la Société de Neuroendocrinologie (SNE). Corte, France.
  • (2016). The delta opioid receptor as a target to reduce morphine tolerance. 37th Annual Scientific Meeting of the Canadian Pain Society. Vancouver, Canada.
  • (2015). Awakening the delta opioid receptor for the treatment of pain. Department of Pharmacology The University of Texas Health Science Center at San Antonio. San Antonio, United States.
  • (2014). A "DOR" for new analgesics. Frontiers in pain research lecture series/The Alan Edwards Centre for Research on Pain/McGill University. Montreal, Canada.
  • (2013). Regulating the delta opioid receptor for pain control. University of Michigan. Ann Arbor, United States.
  • (2013). Role and regulation of the delta opioid receptor. International Narcotics Research Conference. Cairns, Australia.
  • (2012). The delta opioid receptors : Where are they and what are they doing?. Washington University, Department of Anesthesiology, St-Louis, USA. St-Louis, United States.

Les informations disponibles dans la base de données Expertus sont tirées du CV commun canadien.